The participation of prostaglandins in the action of kinins on the central dopaminergic system in the rat. II. Participation of PGF2 alpha in the action of kinins on the central dopaminergic system.
Administration of prostaglandin F2 alpha (PGF2 alpha) in the presence of kinins did not change or potentiated the action of amphetamine (AMPH). Depending on the dose, PGF2 alpha could antagonize or potentiate the effect of kinins on the apomorphine (APO)-induced stereotypy. A combined treatment with PGF2 alpha and kinins did not affect or potentiate the haloperidol (HAL)-induced catalepsy. Bradykinin (BRS) and PGF2 alpha given separately or in combination did not change the levels of dopamine (DA), homovanillic acid (HVA) and noradrenaline (NA) after administration of AMPH, but given in combination elevated the striatal level of DA after treatment with APO. PGF2 alpha given in combination with BRS to rats receiving alpha-methyl-p-tyrosine (alpha-MT) increased the DA turnover in the striatum, while combined treatment with PGF2 alpha BRS, APO and alpha-MT depressed the turnover rate.
D000818:Animals; D001920:Bradykinin / Q000494:pharmacology*; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D006719:Homovanillic Acid / Q000378:metabolism; D007610:Kallikreins / Q000494:pharmacology*; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism*
D011461:Prostaglandins F, Synthetic; D011954:Receptors, Dopamine; D007610:Kallikreins; D001920:Bradykinin; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid